Anticancer-targeted therapies inhibit various kinases implicated in cancer and have been
used in clinical settings for decades. However, many cancer-related targets are proteins …

Targeted protein degradation refers to the use of small molecules to induce the selective
degradation of proteins. In its most common form, this degradation is achieved through …

The protein cereblon (CRBN) is a substrate receptor of the cullin 4-really interesting new
gene (RING) E3 ubiquitin ligase complex CRL4 CRBN. Targeting CRBN mediates selective …

Targeted protein degradation (TPD) represents a revolutionary therapeutic strategy in
disease management, providing a stark contrast to traditional therapeutic approaches like …

Patients with relapsed or refractory (R/R) diffuse large B‐cell lymphoma (DLBCL), ineligible
for or relapsing after autologous stem‐cell transplant or chimeric antigen‐receptor T‐cell …

Introduction The treatment of multiple myeloma (MM) is evolving rapidly. Quadruplet
regimens incorporating proteasome inhibitors, immunomodulatory drugs (IMiDs), and CD38 …

Diffuse large B-cell lymphoma (DLBCL) is an aggressive and biologically heterogeneous
disease. Approximately 40% of patients with DLBCL will experience disease relapse or will …

Targeted therapies, such as small molecule kinase inhibitors, have made significant
progress in the treatment of hematologic malignancies by directly modulating protein activity …

Introduction: Golcadomide is a novel, oral, small-molecule CELMoD® agent that co-opts
cereblon to induce targeted degradation of the transcription factors Ikaros/Aiolos, which are …

IKZF 1 (Ikaros) 和IKZF 3 (Aiolos) 是一种锌指转录因子, 涉及多种信号通路和调节机制,
对免疫细胞发育和内环境稳定尤为关键. IKZF 1/3 过度表达与多种血液系统恶性肿瘤的发生和 …